Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 111 to 120 of 1182 total matches.
Rilpivirine (Edurant) - A New Drug for HIV Infection
The Medical Letter on Drugs and Therapeutics • Aug 22, 2011 (Issue 1371)
as category B (no evidence of risk in animals)
for use during pregnancy.
DRUG INTERACTIONS — Taking ...
The FDA has approved rilpivirine (Edurant –
Janssen), a non-nucleoside reverse transcriptase
inhibitor (NNRTI), for use with other antiretroviral
agents for treatment of HIV-1 infection in treatment-naive
adults. Rilpivirine is also available in a fixed-dose
combination with emtricitabine and tenofovir
(Complera – Gilead).
Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms (online only)
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
Initial
Target Dosage Adverse Effects Drug Interactions Pregnancy/Lactation Comments
Cost1
Opioids ...
View Expanded Table: Some Drugs for Management of Opioid Withdrawal Symptoms
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
. Quinupristin/dalfopristin, which is not commonly
used because of its toxicity and drug interactions ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Comparison Chart: Some Non-Statin Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Jun 08, 2026 (Issue 1756)
–20% ▪ Gastrointestinal adverse effects and drug interactions limit use of bile acid sequestrants ...
View the Comparison Chart: Some Non-Statin Lipid-Lowering Drugs
Med Lett Drugs Ther. 2026 Jun 8;68(1756):e96-8 doi:10.58347/tml.2026.1756c | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
elevations, myalgia, hypersensitivity reactions
▪ Drug interactions: P-gp inhibitors may increase rifaximin ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721f | Show Introduction Hide Introduction
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
adverse effects have been reported and it interacts
with many other drugs.
Crohn’s Disease (CD ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Juluca - A Two-Drug Complete Regimen for HIV (online only)
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
antiretroviral regimen to
simplify treatment, improve tolerability, minimize
toxicity and drug interactions ...
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase
strand transfer inhibitor (INSTI) dolutegravir (Tivicay)
and the non-nucleoside reverse transcriptase
inhibitor (NNRTI) rilpivirine (Edurant), as a once-daily
complete regimen for treatment of adults
with HIV-1 infection who do not have a history of
treatment failure or known substitutions associated
with resistance to either drug and have been taking
a stable suppressive antiretroviral regimen for ≥6
months. Dolutegravir/rilpivirine is the first complete
regimen to be approved for...
Comparison Table: Drugs for Alzheimer's Disease Dementia (online only)
The Medical Letter on Drugs and Therapeutics • Mar 30, 2026 (Issue 1751)
/Formulations Cost1 Usual Dosage Adverse Effects Drug Interactions Comments
NMDA-Receptor Antagonist
Memantine ...
View the Comparison Table: Drugs for Alzheimer's Disease Dementia
Med Lett Drugs Ther. 2026 Mar 30;68(1751):e57-8 doi:10.58347/tml.2026.1751c | Show Introduction Hide Introduction
Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025 (Issue 1721)
are common; administration with food may reduce nausea
▪ Drug interactions: methadone may decrease efficacy ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3 doi:10.58347/tml.2025.1721e | Show Introduction Hide Introduction
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
they
have a functioning pacemaker.
DRUG INTERACTIONS — Concurrent use of a
moderate CYP2C9 inhibitor and moderate ...
The FDA has approved siponimod (Mayzent –
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod is the second
S1P receptor modulator to be approved in the US;
fingolimod (Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients ≥10
years old, was the first. The purine antimetabolite
cladribine (Mavenclad) was also...